"With a strategic review ahead once the incoming chair has started, we see uncertainty elevated in coming months and no clear path to a Return on Equity at the 10-12% rightly identified by management as acceptable," Ryan wrote in a note. Benzinga's Take: Credit Suisse doesn't appear to be in any dire near-term liquidity crunch, and the $4.8 billion Archegos hit is likely already priced into the stock, which is down 23% in the past month. What is much more difficult for investors to judge is just how much damage has been done to Credit Suisse's reputation and how much of a lasting impact Archegos could have on the company's profitability and growth.